{"filing":{"accession_number":"0001104659-26-082433","cik":"0001566044","ticker":"VYNE","company_name":"VYNE Therapeutics Inc.","form":"8-K","filing_date":"2026-07-10","report_date":null,"primary_document":"tm2620182d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1566044/000110465926082433/tm2620182d1_8k.htm"},"events":[{"id":16973,"run_id":15197,"accession_number":"0001104659-26-082433","anchor_item_number":"7.01","event_type":"dividend_distribution","event_domain":"financial","is_material":true,"confidence":0.88,"summary":"VYNE's Board declared a special cash dividend of approximately $16.5 million ($0.38 per share) to stockholders and warrant holders, conditioned on the closing of the proposed merger with Yarrow Bioscience expected July 24, 2026. This represents a material return of capital to shareholders in connection with the pending transaction.","company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","filing_date":"2026-07-10","form":"8-K","submitted_at":null,"items":[{"id":15241,"accession_number":"0001104659-26-082433","item_number":"7.01","item_title":null,"event_type":"dividend_distribution","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"VYNE's Board declared a special cash dividend of an estimated $16.5 million ($0.38 per share) in connection with the proposed merger with Yarrow Bioscience. The dividend is conditioned on merger closing (expected July 24, 2026) and represents a material return of capital to shareholders. While the disclosure also references the merger transaction, the primary action disclosed in this Item 7.01 is the declaration and payment of the special dividend distribution.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T12:07:49.198919+00:00","company_name":"","ticker":null,"filing_date":""},{"id":15242,"accession_number":"0001104659-26-082433","item_number":"8.01","item_title":null,"event_type":"dividend_distribution","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The filing discloses VYNE's board declaration of a special cash dividend of approximately $16.5 million ($0.38 per share) to stockholders and warrant holders in connection with the pending merger with Yarrow Bioscience. While the dividend is conditioned on merger closing (expected July 24, 2026), the board's declaration on July 10, 2026 is the material event disclosed in Item 8.01. The dividend represents a return of capital to shareholders and would materially affect investor assessment of the transaction's value.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T12:07:49.198919+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":15241,"accession_number":"0001104659-26-082433","item_number":"7.01","item_title":null,"event_type":"dividend_distribution","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"VYNE's Board declared a special cash dividend of an estimated $16.5 million ($0.38 per share) in connection with the proposed merger with Yarrow Bioscience. The dividend is conditioned on merger closing (expected July 24, 2026) and represents a material return of capital to shareholders. While the disclosure also references the merger transaction, the primary action disclosed in this Item 7.01 is the declaration and payment of the special dividend distribution.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T12:07:49.198919+00:00","company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","filing_date":"2026-07-10"},{"id":15242,"accession_number":"0001104659-26-082433","item_number":"8.01","item_title":null,"event_type":"dividend_distribution","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The filing discloses VYNE's board declaration of a special cash dividend of approximately $16.5 million ($0.38 per share) to stockholders and warrant holders in connection with the pending merger with Yarrow Bioscience. While the dividend is conditioned on merger closing (expected July 24, 2026), the board's declaration on July 10, 2026 is the material event disclosed in Item 8.01. The dividend represents a return of capital to shareholders and would materially affect investor assessment of the transaction's value.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T12:07:49.198919+00:00","company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","filing_date":"2026-07-10"}]}